Diabetic Retinopathy

It is caused by diabetes mellitus, with the literature framing it as a complication of poorly controlled diabetes over time. The supplied grounding also links diabetic retinopathy to metabolic disturbance in diabetes and to broader diabetic complications.

The disease is primarily a microvascular retinal disorder, with diagnosis and pathology centered on microvascular lesions. The literature also describes inflammatory processes, persistent leukocyte activation, retinal neurodegeneration, decreased reactive oxygen species regulation, and impaired vascular function as contributors to retinal damage; later stages can include pathologic neovascularization.

Diabetes mellitus is the main risk factor, and the literature specifically associates diabetic retinopathy with years of poorly controlled diabetes. Type 2 diabetes-related metabolic disturbance, including insulin resistance and disturbed glucose metabolism, is also linked to the condition.

Treatment is described at the class level as anti-vascular endothelial growth factor therapy, which has shown clinical benefit in diabetic retinopathy. The literature also discusses glucose-lowering incretin-based therapies, including GLP-1 receptor agonists such as semaglutide and DPP-4 inhibitors, as agents of interest for microvascular disease, although their human benefit for retinopathy is not fully established in the supplied grounding.